山东大学耳鼻喉眼学报 ›› 2013, Vol. 27 ›› Issue (5): 8-14.doi: 10.6040/j.issn.1673-3770.0.2013.176

• 论著 • 上一篇    下一篇

新辅助化疗联合同期放化疗与同期放化疗单独治疗鼻咽癌疗效及安全性的Meta分析

徐媛媛,曾泉,洪苏玲,胡国华   

  1. 重庆医科大学附属第一医院耳鼻咽喉科, 重庆 400016
  • 收稿日期:2013-06-15 出版日期:2013-10-16 发布日期:2013-10-16
  • 通讯作者: 胡国华,博士生导师。 Email:hghcq@sina.com
  • 作者简介:徐媛媛。 Email:xyycqyk@163.com
  • 基金资助:

    国家临床重点专科建设项目经费卫办医政函[2012]649号

Comparison of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent  chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A meta analysis.

XU Yuan-yuan, ZENG Quan, HONG Su-ling, HU Guo-hua   

  1. Department of Otolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
  • Received:2013-06-15 Online:2013-10-16 Published:2013-10-16

摘要:

目的    评价新辅助化疗联合同期放化疗(IC+CCRT)治疗局部进展期鼻咽癌的疗效及安全性。方法    计算机检索pubmed、embase、cochrane图书馆、CNKI等数据库有关IC+CCRT与CCRT治疗鼻咽癌的随机对照试验,按照事先设置的标准由两位研究者独立进行筛选、提取相关资料并用RevMan5.1.0软件进行分析。结果    10项RCT共921例患者纳入本研究。Meta分析结果显示,与CCRT相比: ① 近期疗效:IC+CCRT即期颈部淋巴结完全缓解率提高[OR=2.53,95%CI (1.44,4.44),P=0.001],而鼻咽部肿瘤完全缓解率两者差异无统计学意义[OR=1.26,95%CI (0.66,2.40),P=0.16];治疗结束3个月后IC+CCRT鼻咽部肿瘤及颈淋巴结完全缓解率均较前者有所提高[RR=1.07,95%CI(1.02,1.14),P=0.01], [RR=1.11,95%CI (1.02,1.21),P=0.01];②远期疗效:2年总生存率两者差异无统计学意义[OR=1.04, 95%CI(0.97,1.12),P=0.25];③安全性:IC+CCRT治疗过程中除Ⅲ°及以上白细胞下降情况明显外[RR=1.57,95%CI(1.24,1.98),P=0.0002],其余Ⅲ°及以上皮肤反应[RR=1.57,95%CI (0.91,1.96),P=0.14]、口腔黏膜反应   [RR=1.13,95%CI(0.95,1.34),P=0.18]和消化道不良反应[RR=0.99,95%CI (0.72,1.37),P=0.95]两者差异无统计学意义。结论    与CCRT相比,IC+CCRT可以提高近期疗效,但对2年远期总生存率无明显益处,且后者治疗期间白细胞下降更明显。

关键词: 新辅助化疗, 同期放化疗, 鼻咽癌, Meta分析

Abstract:

Objective    To evaluate the efficacy and treatment toxicity of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy compared with concurrent chemoradiotherapy alone in the treatment of locoregionally advanced nasopharyngeal carcinoma. Methods    The search strategy included Pubmed(1978-2013), Embase(1978-2013),the Cochrane Library, China National Knowledge Internet Web (1978-2013), Vipbrowser Database(1978-2013) and Wanfang Database(1978-2013). We also searched reference lists of articles as a complement. RCTs that compared neoadjuvant chemotherapy followed by concurrent chemoradiotherapy(IC+CCRT) with concurrent chemoradiotherapy(CCRT) alone in locoregionally advanced nasopharyngeal carcinoma were included. After study selection, two reviewers assessed and extracted data independently. Meta-analysis was performed by using the RevMan 5.1.0.software. Results    Four studies were included in immediate result of treatment evaluation: compared with CCRT, IC+CCRT got more complete response of cervical lymph nodes[OR=2.53, 95%CI(1.44,4.44)], but had no significant difference between the two groups in the CR of primary lesions (P<0.05). Five studies were included in the short-term efficacy evaluation: compared with the CCRT, IC+CCRT got more complete response of primary lesions and cervical lymph nodes [OR=1.07, 95%CI(1.02,1.14)], [OR=1.11, 95%CI(1.02,1.21)]. Six studies were included in 2 years overall survival evaluation: there had no significant difference between the two groups (P>0.05). There were no treatment-related deaths in both groups of six studies. Ten studies were included in treatment toxicity evaluation: Risk ratios of [OR=1.57, 95%CI(1.24,1.98)], [OR=1.34, 95%CI(0.91,1.96)], [OR=1.13, 95%CI(0.95,1.34)], [OR=0.99, 95%CI(0.72,1.37)]. were observed for leucopenia, dermatitis, mucositis, and gastrointestinal toxicity during the treatment. Conclusion    The neoadjuvant chemotherapy followed by concurrent chemoradiotherapy can improve the shortterm efficacy of treatment but increases the treatment toxicity in local advanced nasopharyngeal carcinoma, and it cannot improve the immediate result and 2-year survival.

Key words: Nasopharyngeal carcinoma, Induced chemotherapy, Neoadjuvant chemotherapy, Chemoradiotherapy

中图分类号: 

  • R739.63
[1] 林兴,林宗通,沈翎. 鼻窦球囊扩张治疗儿童慢性鼻窦炎的系统评价及Meta分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 79-86.
[2] 张彩霞,刘阳云,江文,刘庚勋,曹杭,陈琼,张纪帅. 一氧化氮对鼻咽癌CNE-2细胞株化疗增敏效应的研究[J]. 山东大学耳鼻喉眼学报, 2017, 31(5): 72-78.
[3] 周毅波,龚小蓉,于锋. MiR-150调控Nanog对鼻咽癌侧群细胞增殖、侵袭的影响[J]. 山东大学耳鼻喉眼学报, 2017, 31(5): 79-84.
[4] 张杰,陈雪梅,许安廷. 超声刀扁桃体切除术与低温等离子扁桃体切除术的对比研究[J]. 山东大学耳鼻喉眼学报, 2017, 31(5): 95-100.
[5] 陈婷婷,郭其云,刘佳琪,刘丽庭. 探讨同期放化疗对儿童青少年鼻咽癌患者生活质量的影响[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 55-58.
[6] 王越,柯敏,韩芳芳,王文欢,翁鸿. EX-PRESS引流器植入术与小梁切除术治疗开角型青光眼有效性和安全性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 104-111.
[7] 于斌,郑青平,罗展雄,李旌,周媛媛,李中华,王磊黎,贺婵娟,石丰榕. 重组人表皮生长因子预防鼻咽癌放射性口腔黏膜炎和急性放射性皮炎的疗效观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 95-99.
[8] 王雅宁,耿博,李百彦,崔朝阳,王启荣. 鼻咽癌放疗后颅底骨感染坏死的治疗体会[J]. 山东大学耳鼻喉眼学报, 2016, 30(6): 42-45.
[9] 李泽文,郭俊宇,周洁,严福波,杨志敏,丁珠华. 胃食管反流病与喉癌关系的Meta分析[J]. 山东大学耳鼻喉眼学报, 2016, 30(3): 40-46.
[10] 董频,英信江,陈歆维,邓志宏,张少强,於子卫,金斌,孙臻峰,谢晋,祝江才. 新辅助化疗方案尼妥珠单抗联合奈达铂和5-氟尿嘧啶治疗下咽鳞癌初步临床分析[J]. 山东大学耳鼻喉眼学报, 2016, 30(3): 10-14.
[11] 王君影,李晓峰. 小牛血去蛋白提取物眼用凝胶对鼻咽癌放射治疗后眼角膜内皮细胞损伤的影响[J]. 山东大学耳鼻喉眼学报, 2016, 30(1): 76-79.
[12] 赵燕恋, 卢永田, 杨继红, 张娟, 苗芳芳, 李洁萍. 鼻咽癌EGFL7的表达与肿瘤侵袭转移的关系[J]. 山东大学耳鼻喉眼学报, 2015, 29(6): 31-35.
[13] 车娟, 赵洪春, 李金玲, 王延飞. D-二聚体与鼻咽癌预后的关系[J]. 山东大学耳鼻喉眼学报, 2015, 29(5): 47-49.
[14] 陈曦, 李进让. 鼻用激素治疗儿童阻塞性睡眠呼吸暂停低通气综合征疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2015, 29(2): 9-11.
[15] 周慧, 黄雪琴, 胡俊丽, 姚俊, 张月飞, 江枫. 黄芩苷对鼻咽癌化疗期间激素使用影响的实验研究[J]. 山东大学耳鼻喉眼学报, 2014, 28(4): 30-32.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!